Portfolio expansion achieved with acquisition of Galidesivir
Filed with ASX · · 6 pages · English
Summary by 6ix AI
The acquisition was expedited following a thorough due diligence process and will allow Island to focus on developing treatments for high-priority viral infections such as Marburg. The company plans to leverage the FDA’s Animal Rule to potentially fast-track the approval process for Galidesivir, which has a significant development history and funding support. This strategic move is expected to enhance Island's position in the antiviral market, particularly against serious viral threats.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Island Pharmaceuticals Ltd on 6ix
In the deck
Story so far
Earlier from Island Pharmaceuticals
- Successful Phase 2 clinical trial of ISLA-101
- Island completes $3.6 million placement
- Quarterly Activities & Cashflow Report
- Phase 2a/b clinical trial update
- Completion of patient dosing in Phase 2b clinical trial
Later from Island Pharmaceuticals
- Completion of Galidesivir transaction
- Options exercise from existing substantial shareholder
- Preliminary Final Report
- FDA meeting request lodged for Galidesivir
- FDA Meeting request granted
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals